Singapore Clinical Trial: A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigat... Read More

Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants with Obesity or Overweight who are Otherwise Healthy.

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate t... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy ... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy ... Read More

Singapore Clinical Trial: A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, m... Read More

Singapore Clinical Trial: A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability ... Read More

Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab... Read More

Singapore Clinical Trial: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety o... Read More

Singapore Clinical Trial: A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease

Singapore, July 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Effic... Read More

'Modi ji, what happened to your promise?' Rahul Gandhi slams police crackdown on Bihar student protesters

Guwahati, July 27 -- Leader of Opposition in the Lok Sabha Rahul Gandhi on Monday accused the Centre of failing to honour its assurance that no action would be taken against student protesters, allegi... Read More

• ««
• «
• 10646
• 10647
• 10648
• 10649
• 10650
• 10651
• 10652
• 10653
• 10654
• 10655
• »
• »»